



## Transgene Announces Upcoming Investor Meetings

---

**Strasbourg, France, December 18, 2017, 6:00 pm CET** – Transgene (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.

**Transgene will meet institutional investors from January 7 to 11, 2018, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.**

The Company will also attend:

- **Oddo Forum:** January 11 & 12, 2018 – Lyon, France
- **Portzamparc MidCap Conference:** April 4, 2018 – Paris, France
- **Small Cap Event:** April 16 & 17, 2018 – Paris, France
- **Kempen Life Sciences Conference:** April 18 & 19, 2018 – Amsterdam, Netherlands

### **Contacts**

#### **Transgene:**

**Lucie Larguier**  
Director Corporate Communications & IR  
+33 (0)3 88 27 91 04  
[investorrelations@transgene.fr](mailto:investorrelations@transgene.fr)

#### **Media contacts:**

**Citigate Dewe Rogerson**  
David Dible / Marine Perrier  
+ 44 (0)20 7638 9571  
[transgene@citigatedr.co.uk](mailto:transgene@citigatedr.co.uk)

### **About Transgene**

Transgene (Euronext Paris: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical and preclinical development, including TG1050 (chronic hepatitis B) and TG6002 (solid tumors). Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China.

Additional information about Transgene is available at [www.transgene.fr](http://www.transgene.fr).

Follow us on Twitter: [@TransgeneSA](https://twitter.com/TransgeneSA)